Joshua Jennings
Stock Analyst at TD Cowen
(3.31)
# 1,024
Out of 5,154 analysts
81
Total ratings
46.75%
Success rate
4.15%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BFLY Butterfly Network | Maintains: Buy | $4.5 → $6 | $3.65 | +64.38% | 1 | Feb 27, 2026 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $50 → $34 | $24.22 | +40.38% | 5 | Feb 26, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $115 → $100 | $71.35 | +40.15% | 8 | Feb 5, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $222 → $250 | $240.40 | +3.99% | 2 | Jan 22, 2026 | |
| EW Edwards Lifesciences | Upgrades: Buy | $90 → $97 | $81.64 | +18.81% | 2 | Jan 9, 2026 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $15 | $4.32 | +247.22% | 1 | Dec 10, 2025 | |
| CBLL CeriBell | Maintains: Buy | $36 → $20 | $17.83 | +12.17% | 3 | Nov 5, 2025 | |
| SENS Senseonics Holdings | Maintains: Buy | $25 → $15 | $5.96 | +151.68% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Buy | $100 → $84 | $68.10 | +23.35% | 2 | Oct 31, 2025 | |
| HUMA Humacyte | Maintains: Buy | $5 → $3.5 | $1.11 | +215.32% | 3 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $6.20 | +141.94% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $264 → $324 | $237.01 | +36.70% | 1 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $120 | $129.61 | -7.41% | 9 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $143 → $119 | $94.11 | +26.45% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $60 | $33.71 | +77.99% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $78.72 | +1.63% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $3.18 | +1,315.09% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $17.69 | +126.12% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $364.56 | +9.72% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $70.41 | -14.78% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $21.14 | +60.83% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $5.31 | +238.98% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $17.01 | +46.97% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $109.56 | +18.66% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $2.05 | +143.90% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $90.90 | +28.71% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $12.23 | -1.88% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $167.12 | +64.55% | 1 | Feb 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $28 | $10.05 | +173.63% | 3 | Sep 5, 2018 |
Butterfly Network
Feb 27, 2026
Maintains: Buy
Price Target: $4.5 → $6
Current: $3.65
Upside: +64.38%
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Buy
Price Target: $50 → $34
Current: $24.22
Upside: +40.38%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $115 → $100
Current: $71.35
Upside: +40.15%
Johnson & Johnson
Jan 22, 2026
Maintains: Buy
Price Target: $222 → $250
Current: $240.40
Upside: +3.99%
Edwards Lifesciences
Jan 9, 2026
Upgrades: Buy
Price Target: $90 → $97
Current: $81.64
Upside: +18.81%
Orchestra BioMed Holdings
Dec 10, 2025
Initiates: Buy
Price Target: $15
Current: $4.32
Upside: +247.22%
CeriBell
Nov 5, 2025
Maintains: Buy
Price Target: $36 → $20
Current: $17.83
Upside: +12.17%
Senseonics Holdings
Nov 5, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $5.96
Upside: +151.68%
DexCom
Oct 31, 2025
Maintains: Buy
Price Target: $100 → $84
Current: $68.10
Upside: +23.35%
Humacyte
Aug 12, 2025
Maintains: Buy
Price Target: $5 → $3.5
Current: $1.11
Upside: +215.32%
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $6.20
Upside: +141.94%
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $237.01
Upside: +36.70%
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $129.61
Upside: -7.41%
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $94.11
Upside: +26.45%
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $33.71
Upside: +77.99%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $78.72
Upside: +1.63%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $3.18
Upside: +1,315.09%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $17.69
Upside: +126.12%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $364.56
Upside: +9.72%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $70.41
Upside: -14.78%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $21.14
Upside: +60.83%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $5.31
Upside: +238.98%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $17.01
Upside: +46.97%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $109.56
Upside: +18.66%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $2.05
Upside: +143.90%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $90.90
Upside: +28.71%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $12.23
Upside: -1.88%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $167.12
Upside: +64.55%
Sep 5, 2018
Downgrades: Market Perform
Price Target: $28 → $28
Current: $10.05
Upside: +173.63%